Moderna gave investors three distinct pieces of news to chew on this week: a swing back into profit, a sharply raised growth target, and a quiet legal settlement with GSK. The market focused on the first two, sending the shares up 5.7% on Friday. The third may matter just as much over the longer haul.
From red to black
For the third quarter of 2026, Moderna booked revenue of USD 1.31 billion and a net profit of USD 162 million — a reversal from the loss recorded in the same period a year earlier. Sales climbed 29% year over year, and diluted earnings per share came in at USD 0.38.
US revenue reached USD 780 million, with international markets contributing USD 533 million. Management expects roughly a 50/50 split between domestic and overseas sales for the full year.
CEO Stéphane Bancel credited new products, geographic expansion, international COVID vaccine sales and cost cuts for the improvement — meaning the gains came from both the top line and the expense side. Shipping timing also flattered the quarter, so the durability of the demand trend across individual delivery periods is the metric that matters from here.
Guidance gets a lift
The headline number for many investors was the revised outlook. Moderna now projects full-year 2026 revenue growth of 15% to 25%, up from a prior ceiling of 10%. On the spending side, expected research and development outlays for 2026 were trimmed to USD 2.7 billion from USD 2.9 billion.
That combination — faster growth, lighter R&D — is what turned heads. Yet the cash picture tempers the enthusiasm. Operating activities consumed USD 2.72 billion in the first nine months of 2026, and the net loss for that stretch totaled USD 1.96 billion. A single profitable quarter strengthens the earnings trajectory, but funding needs are judged over longer horizons. The next real test is whether growth and spending discipline can hold together, and the improvement would be most convincing if operating cash burn declines alongside it.
Should investors sell immediately? Or is it worth buying Moderna?
GSK deal removes a legal overhang
Beyond the income statement, Moderna and GSK agreed on 28 October to settle all pending disputes between them in the US and Europe. The two companies will grant each other patent licenses covering infectious diseases, with no payments attached to the arrangement.
The terms are favorable for Moderna: the cross-licenses come free of royalty obligations and form part of the broader resolution. It is a structural point that sits behind the growth debate — the conditions under which a company can use its patent rights shape the economics just as much as revenue and earnings do.
Pipeline cuts both ways
Moderna and Merck also reported positive Phase III results for Intismeran in melanoma. Combined with Keytruda, the therapy reduced the risk of recurrence or death by 42%. Two-year recurrence-free survival stood at 82.2%, compared with 70% in the control arm. Moderna aims to file for approval in 2026 and hopes for a green light in 2027.
Not every program is advancing. An interim Phase III analysis of the norovirus vaccine failed to meet the criteria for early success, and no additional cohort is planned for this winter. The melanoma data open a further development path — provided the regulatory route goes to plan — while the norovirus setback is a reminder that clinical risk remains.
What to watch next
Moderna has scheduled an analyst day focused on oncology for 12 November 2026, giving the post-earnings discussion a concrete next date. The raised guidance and the quarterly profit are operational arguments in the company’s favor; how long they last will be settled by further sales, cost control and the success of its development programs.
Ad
Moderna Stock: Buy or Sell?! New Moderna Analysis from November 8 delivers the answer:
The latest Moderna figures speak for themselves: Urgent action needed for Moderna investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 8.
Moderna: Buy or sell? Read more here...
